Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266460 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01266460: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT01266460 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01266460, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.
Primary Outcome
Number of patients with dose-limiting toxicities, as assessed by CTCAE v 4.0
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-05-23 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 2 |
What the finished NCT01266460 record still lists
NCT01266460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01266460 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01266460 about?
NCT01266460 is a clinical study titled "Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer". This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cel...
What is the current status of trial NCT01266460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2011-05-23. Estimated completion is 2018-10-02.
What interventions are being tested in trial NCT01266460?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01266460?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01266460's enrollment target sits among peer trials
54 1160th of 2000 higher than 830 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI